Latest Thesis
Hims and Hers Health: Decoding The Business Model Pivot Toward GLP-1 Weight Loss
Hims is using GLP-1 weight loss to expand the platform, but the quality test is retention and cash flow.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
Hims and Hers Health: Decoding The Business Model Pivot Toward GLP-1 Weight LossHims is using GLP-1 weight loss to expand the platform, but the quality test is retention and cash flow.NYSEJun 5, 2026Research reportReadSlides
HIMS closed Eucalyptus. The global-platform claim just got real.Hims & Hers completed the Eucalyptus acquisition on June 2, 2026. The close upgrades the scale story, but the real proof still has to show up in international revenue mix, retention, margins, and cash flow.NYSEJun 5, 2026Research reportReadSlides
HIMS quietly added a retention weapon. Now the numbers have to prove it.Hims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.NYSEMay 29, 2026Research reportReadSlides
HIMS this week: Canada GLP-1 expansion meets a $402.5M convert testHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.NYSEMay 22, 2026Research reportReadSlides
Hims & Hers (HIMS): the consumer-health platform has scale; the proof test is mix qualityPrimary-source Coverage Bootstrap of Hims & Hers, covering revenue scale, subscriber growth, GLP-1 mix shift, international expansion, cash generation, and the proof gates needed before higher conviction.NYSEMay 12, 2026Research reportReadSlides
Hims & Hers: Q1 2026 raises revenue guidance but confirms margin resetHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.NYSEMay 11, 2026Research reportReadSlides